US EditionStudy: Immune therapy works as well in senior cancer patients as in younger adults
- Researchers at Johns Hopkins reported in April 2025 that ICIs are effective for older cancer patients.
- Most solid tumor cancer diagnoses occur in adults aged 65+, making effective treatment in this age group vital.
- The study examined about 100 patients, evenly split between those older or younger than age 65.
- According to senior author Dr. Daniel Zabransky, immune checkpoint inhibitors are given without major age consideration currently.
- The findings suggest personalized immunotherapies can improve survival and quality of life for older adults facing cancer.
47 Articles
47 Articles
Study: Immune therapy works as well in senior cancer patients as in younger adults
Seniors with cancer respond just as well as younger patients to immune checkpoint inhibitors -- drugs that take the brakes off the immune system so it can target and kill cancer cells more effectively, a study says.
InsideNoVA.com
Immune Therapy Works As Well In Senior Cancer Patients As In Younger Adults
Key Takeaways
Cancer immunotherapy effective across all ages despite immune differences
Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune system differences, according to a study by researchers from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy, and the Johns Hopkins Convergence Institute.
Older adults respond well to immunotherapy despite age-related immune system differences, researchers find
Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune system differences, according to a study by researchers from the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy, and the Johns Hopkins Convergence Institute.
PDAP1 as an Accelerator of Human Aging
A great many studies have used large human population data sets to show statistical relationships between specific gene variants or specific protein levels on the one hand and age-related disease and mortality on the other. Near all of these relationships represent a small effect size, and further fail to replicate in different study populations. Still, researchers keep trying. Some successful replications have been achieved, and a few genes and…
Coverage Details
Bias Distribution
- 48% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
